美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

亚盛医药

17.00

-0.3200-1.85%

盘后：17.000.00000.00%19:30 EDT

成交量：1,838

成交额：3.14万

市值：15.87亿

市盈率：-8.61

高：17.44

开：17.15

低：17.00

收：17.32

52周最高：48.45

52周最低：16.36

股本：9,333.04万

流通股本：7,158.28万

量比：0.19

换手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-1.9750

每股收益(LYR):-1.9957

净资产收益率：-236.63%

总资产收益率：-28.04%

市净率：19.16

市盈率(LYR):-8.52

数据加载中...

总览公司新闻资讯公告

亚盛医药上半年亏损同比扩大至8.17亿元

亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速

亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话

财报前瞻｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观

亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化

亚盛医药任命首席业务拓展官和首席商务运营官

亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官

【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜

亚盛医药启动2亿美元ATM融资计划，加速奥雷巴替尼及Lisaftoclax商业化进程

亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位

【EHA2026】亚盛医药多项临床数据亮相，彰显血液肿瘤领域全球创新实力

亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展

亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股

亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股

国泰海通证券：首予亚盛医药(06855)“增持”评级目标价59.09港元

智通财经网

【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，"星光计划"品种潜力初显

【直击ASCO 2026】亚盛医药耐立克®治疗CML-LBP与Ph+ BCP-ALL数据发布，有望填补急变期治疗空白

【直击ASCO 2026】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，长期疗效再获验证

达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放

亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/AAPG/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":17,"timestamp":1787342400000,"preClose":17.32,"halted":0,"volume":1838,"hourTrading":{"tag":"盘后","latestPrice":17,"preClose":17,"latestTime":"19:30 EDT","volume":42,"amount":715.11,"timestamp":1787355007860,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.018475750577367223,"floatShares":71582800,"shares":93330405,"eps":-1.975,"marketStatus":"休市中","change":-0.32,"latestTime":"08-21 16:00:00 EDT","open":17.15,"high":17.4435,"low":17,"amount":31414.382856000004,"amplitude":0.025606,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.975,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":17.32,"postHourTrading":{"tag":"盘后","latestPrice":17,"preClose":17,"latestTime":"19:30 EDT","volume":42,"amount":715.11,"timestamp":1787355007860,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.19047816661684647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-28.04%","roe":"-236.63%","lyrEps":-1.995679,"volumeRatio":0.19047816661684647,"shares":93330405,"dividePrice":0,"high":17.4435,"amplitude":0.025606,"preClose":17.32,"low":17,"week52Low":16.36,"pbRate":"19.16","psRate":"16.59","week52High":48.45,"institutionHeld":0,"latestPrice":17,"eps":-1.975,"divideRate":0,"volume":1838,"delay":0,"ttmEps":-1.975,"open":17.15,"prevYearClose":26.24,"prevWeekClose":19,"prevMonthClose":17.425,"prevQuarterClose":17.56,"fiveDayClose":19,"twentyDayClose":18.29,"sixtyDayClose":20.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":-0.44,"defaultRemindTime":1787126400000,"name":null,"time":"盘前","dateTimestamp":1787112000000,"actualEps":null},{"date":"2026-03-25","symbol":"AAPG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":null,"defaultRemindTime":1774468800000,"name":null,"time":"盘后","dateTimestamp":1774411200000,"actualEps":null},{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.7778,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7778,"analysts":9,"updateTime":1781150400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-08-21","current":-8.607595,"percent":1,"low":-76.454813,"twenty":-35.947221,"median":-19.05933,"eighty":-11.591162,"high":-7.057849,"avg":-25.155962,"sd":16.844147,"marketCap":1541157743.83},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44},{"date":"2026-03-13","current":-12.688953,"twenty":-40.378179,"median":-26.74375,"eighty":-16.137082,"marketCap":2141399622.46},{"date":"2026-03-20","current":-11.937263,"twenty":-39.521832,"median":-25.944924,"eighty":-15.566094,"marketCap":2005434649.33},{"date":"2026-03-27","current":-12.020857,"twenty":-39.289753,"median":-24.396919,"eighty":-15.439715,"marketCap":2161491459.44},{"date":"2026-04-02","current":-13.548587,"twenty":-39.152841,"median":-23.731199,"eighty":-15.186721,"marketCap":2444436047.79},{"date":"2026-04-10","current":-12.693217,"twenty":-38.895939,"median":-23.387346,"eighty":-14.745986,"marketCap":2308441702.51},{"date":"2026-04-17","current":-13.620079,"twenty":-38.882244,"median":-22.946281,"eighty":-14.465216,"marketCap":2481253103.51},{"date":"2026-04-24","current":-12.083101,"twenty":-38.84865,"median":-22.780777,"eighty":-14.008358,"marketCap":2199221373.05},{"date":"2026-05-01","current":-11.527627,"twenty":-38.758432,"median":-22.499202,"eighty":-13.791914,"marketCap":2098243441.9},{"date":"2026-05-08","current":-10.968155,"twenty":-38.515761,"median":-22.389807,"eighty":-13.684651,"marketCap":2004129088.99},{"date":"2026-05-15","current":-10.082774,"twenty":-38.444183,"median":-22.266298,"eighty":-13.539734,"marketCap":1846775928.57},{"date":"2026-05-22","current":-10.707594,"twenty":-38.225934,"median":-22.137659,"eighty":-13.395768,"marketCap":1956144727.44},{"date":"2026-05-29","current":-10.055476,"twenty":-38.129026,"median":-21.923528,"eighty":-13.314281,"marketCap":1843351578.24},{"date":"2026-06-05","current":-8.909894,"twenty":-37.937734,"median":-21.785524,"eighty":-13.216389,"marketCap":1635661877.38},{"date":"2026-06-12","current":-8.93641,"twenty":-37.865895,"median":-21.603031,"eighty":-13.157057,"marketCap":1639076784.73},{"date":"2026-06-18","current":-8.353042,"twenty":-37.752402,"median":-21.278471,"eighty":-13.101714,"marketCap":1535636323.4},{"date":"2026-06-26","current":-7.824164,"twenty":-37.62092,"median":-21.066691,"eighty":-13.023474,"marketCap":1430786980.62},{"date":"2026-07-02","current":-8.952074,"twenty":-37.472757,"median":-20.67449,"eighty":-12.989985,"marketCap":1637864621.41},{"date":"2026-07-10","current":-9.338033,"twenty":-37.371981,"median":-19.946515,"eighty":-12.776282,"marketCap":1707700089.2},{"date":"2026-07-17","current":-9.151372,"twenty":-36.963176,"median":-19.801335,"eighty":-12.672971,"marketCap":1678950333.06},{"date":"2026-07-24","current":-9.04646,"twenty":-36.577605,"median":-19.676085,"eighty":-12.361815,"marketCap":1659751775.25},{"date":"2026-07-31","current":-8.626077,"twenty":-36.450857,"median":-19.539859,"eighty":-12.179575,"marketCap":1585151449.4},{"date":"2026-08-07","current":-9.281807,"twenty":-36.322679,"median":-19.321494,"eighty":-11.987055,"marketCap":1708580872.07},{"date":"2026-08-14","current":-9.158138,"twenty":-36.125575,"median":-19.172925,"eighty":-11.879713,"marketCap":1687515849.52},{"date":"2026-08-21","current":-7.057849,"twenty":-35.947221,"median":-19.05933,"eighty":-11.591162,"marketCap":1541157743.83}],"updateTime":1787488530465},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660472128","title":"亚盛医药上半年亏损同比扩大至8.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472128","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660472128?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 09:38","pubTimestamp":1787189880,"startTime":"0","endTime":"0","summary":"8月20日，亚盛医药（06855）发布截至2026年6月30日止6个月的未经审计综合业绩。报告期内，公司收益为3.02亿元，按固定汇率计算，同比增长29.3%；归母净亏损为8.17亿元，而去年同期亏损5.91亿元。2026年上半年，公司的行政开支达1.19亿元，同比增长19.3%，主要是由于购股权及受限制股份单位开支增加所致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847307477.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847307477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1574","AAPG","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660347943","title":"亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660347943","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660347943?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 07:36","pubTimestamp":1787182583,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，亚盛医药今日公布2026年中期业绩。2026年上半年，公司实现总收入3.02亿元人民币，同比增长29%。在耐立克与利生妥两大商业化产品的双引擎驱动下，公司自我造血能力持续加强。报告期内，公司产品销售收入达到人民币2.82亿元，同比增长33%。截至报告期末，公司总货币资金约19亿元人民币，资金储备充足，为全球研发与商业化拓展提供坚实支撑。亚盛医药正全面快速推进这些全球注册III期临床研究，全球创新将迎来收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855","BK1574","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168288","title":"亚盛医药受邀出席Evercore第二届中国生物科技峰会并参加炉边谈话","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168288","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659168288?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 21:13","pubTimestamp":1786626780,"startTime":"0","endTime":"0","summary":"中国苏州2026年8月13日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司管理层将出席于2026年8月17日-19日在上海浦东丽思卡尔顿酒店举办的Evercore第二届中国生物科技峰会。会议期间，公司管理层将参与由Evercore研究团队主持的炉边谈话，并开展一对一投资者交流会。因此，该等前瞻性陈述不应被视为对未来事件的预测。无论出现新信息、未来事件或其他情况，亚盛医药均无义务更新或修订任何前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5025874_ZH25874_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK4139","EVR","BK1574","06855","BK4127","KURE","03069","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181890937","title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1181890937","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181890937?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 09:37","pubTimestamp":1786498646,"startTime":"0","endTime":"0","summary":"亚盛医药将于2026年08月19日美股盘前发布最新季度财报，市场聚焦盈利改善节奏与商业化推进进度。市场一致预期显示，本季度亚盛医药营收预计为5,097.60万美元，同比增加58.18%；调整后每股收益预计为-0.26美元，同比改善73.17%；EBIT预计为-1.17亿美元，同比下降43.11%；由于缺乏公司端明确口径，毛利率与净利润或净利率的本季度量化指引未见披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜亚盛医药本季度营收预计增58.18%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656419833","title":"亚盛医药聘任CBO、CCO分管全球业务拓展及海外商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656419833","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656419833?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 09:11","pubTimestamp":1785719460,"startTime":"0","endTime":"0","summary":"8月3日，亚盛医药（06855）发布公告，公司宣布两项高管任命，聘任FaialMiyara博士担任CBO统筹全球业务拓展，JimZiegler出任CCO，负责大中华区以外全球产品商业化运营，二人直接向董事长兼首席执行官杨大俊博士汇报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829261521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829261521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2294711713.HKD","LU2357125470.USD","BK1161","BK4139","AAPG","CCO","LU0823414551.USD","BK1574","LU2506951792.HKD","BK4009","06855","LU0823414478.USD","LU2249611893.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656845349","title":"亚盛医药任命首席业务拓展官和首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656845349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656845349?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 08:25","pubTimestamp":1785716700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346342","title":"亚盛医药(06855)任命Faiçal Miyara博士为首席业务拓展官，任命Jim Ziegler为首席商务运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346342?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 07:37","pubTimestamp":1785713832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，公司任命Faial Miyara博士为首席业务拓展官，负责亚盛医药的全球业务拓展工作;并任命Jim Ziegler为首席商务运营官，负责公司产品在大中华地区以外的全球市场的商业化运营。Miyara博士和Ziegler先生直接向公司董事长兼首席执行官杨大俊博士汇报。Miyara博士在全球大型制药公司和生物技术公司中拥有超过20年的肿瘤领域商务拓展经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","AAPG","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654992650","title":"【祝贺】亚盛医药杨大俊荣登《The Medicine Maker》2026全球最具影响力人物榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2654992650","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654992650?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 10:26","pubTimestamp":1785119160,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年7月27日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司董事长兼首席执行官杨大俊博士荣登国际知名医药产业媒体《The Medicine Maker》2026年度\"The Power List\"，在小分子领域TOP10名单中位居第三位。《The Medicine Maker》是全球制药产业链极具影响力的专业媒体，聚焦药物研发、CMC 工艺开发、产业化落地与新药商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5012304_ZH12304_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","06855","BK1574","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294251","title":"亚盛医药启动2亿美元ATM融资计划，加速奥雷巴替尼及Lisaftoclax商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294251","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294251?lang=zh_cn&edition=fundamental","pubTime":"2026-07-19 19:42","pubTimestamp":1784461320,"startTime":"0","endTime":"0","summary":"7月19日，亚盛医药（06855）发布公告，宣布于2026年7月20日向美国证券交易委员会提交了一份F-3表格的注册声明，计划通过建议ATM计划按市价出售最多达2亿美元的美国存托股份。此次计划的实施将允许公司灵活控制股份的出售时间和数量，且不需要在香港进行公开发售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607193811765025.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607193811765025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06855","BK1574","BK1161","AAPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858376","title":"亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858376","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647858376?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 08:53","pubTimestamp":1782780809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，截至本公告日期，已根据2021年受限制股份单位计划向2021年受限制股份单位计划的453名获选人士授出44.07万份受限制股份单位，相当于44.07万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK1574","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2643122602","title":"【EHA2026】亚盛医药多项临床数据亮相，彰显血液肿瘤领域全球创新实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2643122602","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643122602?lang=zh_cn&edition=fundamental","pubTime":"2026-06-15 09:25","pubTimestamp":1781486700,"startTime":"0","endTime":"0","summary":"展示数据涉及公司两大重磅产品——中国首个上市的第三代BCR-ABL抑制剂奥雷巴替尼和中国首个上市的国产原创Bcl-2选择性抑制剂利沙托克拉，全面展现了公司在血液肿瘤领域的深厚布局和全球创新实力。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。亚盛医药首席医学官翟一帆博士表示：\"本届EHA年会上，奥雷巴替尼、利沙托克拉的多项临床进展获得展示，进一步证实了这两款重磅产品在全球血液肿瘤领域的治疗价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4983227_ZH83227_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4983227_ZH83227_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK4139","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228118","title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228118","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228118?lang=zh_cn&edition=fundamental","pubTime":"2026-06-15 07:29","pubTimestamp":1781479754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 公布，公司核心产品的17项临床进展已在2026年欧洲血液学协会年会上精彩亮相，其中包括8项壁报展示。2026年欧洲血液学协会 年会于2026年6月11日至2026年6月14日在瑞典斯德哥尔摩举办。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642287999","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642287999?lang=zh_cn&edition=fundamental","pubTime":"2026-06-11 21:31","pubTimestamp":1781184682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月11日，受托人就2022年受限制股份单位计划目的于场内购买合共11万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426730","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642426730?lang=zh_cn&edition=fundamental","pubTime":"2026-06-10 20:54","pubTimestamp":1781096082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月10日，受托人就2022年受限制股份单位计划目的于场内购买合共19万股现有股份以在归属后满足受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06855","AAPG","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937177","title":"国泰海通证券：首予亚盛医药(06855)“增持”评级 目标价59.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937177","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640937177?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 16:58","pubTimestamp":1780304322,"startTime":"0","endTime":"0","summary":"2025年，公司商业化成果显著，实现总收益5.74亿元，不考虑武田付款同比增长90%，其中，奥雷巴替尼实现收入4.35亿元，利沙托克拉实现7085万元，合计5.06亿元。2025年末现金余额为24.7亿元，现金储备稳健，可以支撑到2027年。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","AAPG","02611","EWH","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982786","title":"【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，\"星光计划\"品种潜力初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982786","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640982786?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:40","pubTimestamp":1780278000,"startTime":"0","endTime":"0","summary":"此次快速口头报告的研究进展初步展现了APG-115在儿童相关实体瘤患者中的抗肿瘤活性和安全性。此次在ASCO 展示的数据证实，APG-115 单药及联合利沙托克拉展现出良好耐受性与显著抗肿瘤活性，尤其是CR 病例令人鼓舞。此次在ASCO展示的研究为APG-115治疗儿童实体瘤患者的数据首次亮相，初步展现的疗效和耐受性令人鼓舞。值得一提的是，APG-115此前已获CDE纳入'星光计划'，拟开发用于多种儿童实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["APG","AAPG","BK1161","BK4139","BK1574","06855","BK4129","LU2125909759.SGD","LU1923622291.USD","LU2125909916.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982781","title":"【直击ASCO 2026】亚盛医药耐立克®治疗CML-LBP与Ph+ BCP-ALL数据发布，有望填补急变期治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982781","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640982781?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 09:02","pubTimestamp":1780275720,"startTime":"0","endTime":"0","summary":"\" 亚盛医药首席医学官翟一帆博士表示：\"此次快速口头报告的研究首次在国际患者中验证了耐立克联合贝林妥欧单抗针对CML-LBP与R/R Ph+ BCP-ALL的治疗潜力。此次展示的数据非常令人鼓舞，有望填补急变期治疗的长期空白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972102_ZH72102_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972102_ZH72102_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1571399168.USD","BK1574","LU0985320562.USD","ALL","AAPG","LU1699723380.USD","LU2355687059.USD","BK1161","BK4107","BK4585","BK4139","BK4588","BK4533","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640784982","title":"【直击ASCO 2026】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，长期疗效再获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2640784982","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640784982?lang=zh_cn&edition=fundamental","pubTime":"2026-06-01 08:59","pubTimestamp":1780275540,"startTime":"0","endTime":"0","summary":"今年是亚盛医药连续第九年亮相ASCO年会，此次公司三个重点品种共有六项研究入选，其中三项获快速口头报告。此外，亚盛医药已经与跨国制药企业武田就耐立克签署了一项独家选择权事宜。在既往接受二代TKI治疗的患者中仍保持较高疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4972100_ZH72100_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972100_ZH72100_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","AAPG","LU1989763427.SGD","06855","LU1989763690.USD","BK1574","BK1161","BK4016","BK4139","CP","LU1261432733.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645908","title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645908","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639645908?lang=zh_cn&edition=fundamental","pubTime":"2026-05-29 11:23","pubTimestamp":1780025014,"startTime":"0","endTime":"0","summary":"财报显示，2025年，亚盛医药实现营业收入5.74亿元，且截至目前市值已超过百亿港元。而耐立克和利生妥两大十亿美元分子相继获批上市并在终端市场实现快速放量，便是亚盛医药能够顺利达成18A“摘B”里程碑的重要原因。智通财经APP了解到，亚盛医药今年六项重磅研究成果入选2026年ASCO年会。以上无疑都将成为亚盛医药年内的重要催化。近年来已有10数家18A企业顺利“摘B”，并在“摘B”后实现了可观的估值增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638992766","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638992766","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638992766?lang=zh_cn&edition=fundamental","pubTime":"2026-05-28 21:58","pubTimestamp":1779976713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月28日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}